 |
인쇄하기
취소
|
LG Life Sciences to conduct Phase 3 clinical trials over new diabetes treatment
LG Life Sciences (LGLS), a Korean pharmaceutical manufacturer, said on September 22 that it will begin Phase III clinical trials for LC15-0444, a new anti-diabetic agent, in Korea and India.
LC15-0444, a dipeptidyl peptidase-4 (DPP-4) enzyme, is one of a new class of oral hypoglycemics that is expected to quickly replace the currently most-prescribed thiazolidinediones (TZDs). LC15-0444 is e...
LC15-0444, a dipeptidyl peptidase-4 (DPP-4) enzyme, is one of a new class of oral hypoglycemics that is expected to quickly replace the currently most-prescribed thiazolidinediones (TZDs). LC15-0444 is e...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.